LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

{
  "signal_id": "0800a1e3-3cc3-8ef9-5c01-50511ffd4efe",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-16T06:00:00+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/16/3362836/0/en/leqembi-pen-subcutaneous-formulation-of-leqembi-approved-in-japan-for-the-treatment-of-early-alzheimer-s-disease.html",
    "title": "LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease",
    "excerpt": "TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI ® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI ® ” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration. LEQEMBI Pen is an autoinjector formulation that enables administration by a care partner or patient self-administration, with two pens (totaling 500 mg) administered once weekly. With this approval, LEQEMBI treatment now offers a new option of once-weekly SC administration at home*, in addition to intravenous (IV) administration every two weeks in a hospital setting. LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. The improved convenience and flexibility of treatment with LEQEMBI is expected to lower barriers to initiating and continuing treatment with LEQEMBI. Furthermore, LEQEMBI Pen also has the potential to reduce healthcare...",
    "product": "LEQEMBI Pen",
    "summary": "Biogen and its partner Eisai have received approval in Japan for LEQEMBI Pen, a subcutaneous autoinjector formulation of their early Alzheimer's disease treatment, LEQEMBI.",
    "location": "Japan",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182",
    "confidence": 0.9,
    "product_data": {
      "name": "LEQEMBI Pen",
      "full_text": "“LEQEMBI ® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI ® ”",
      "fuzzy_match": false,
      "release_type": "formulation"
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-16T06:00:00Z",
    "location_data": [
      {
        "region": "Eastern Asia",
        "country": "Japan",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-16",
    "article_sentence": "Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI ® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI ® ” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration.",
    "related_company_name": "Eisai Co., Ltd.",
    "related_company_domain": "eisai.com"
  }
}

curl https://signals.autobound.ai/v1/signals/0800a1e3-3cc3-8ef9-5c01-50511ffd4efe \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'